Disease/Infection News

RSS

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time.

4 Aug 2015

Penn Medicine devises new approach to develop vaccines against lethal diseases

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination.

4 Aug 2015

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University.

4 Aug 2015

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa.

4 Aug 2015

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Researchers at the Johns Hopkins University School of Medicine, Johns Hopkins University Department of Chemical and Biomolecular Engineering, and Federal University of Rio de Janeiro in Brazil have designed a DNA-loaded nanoparticle that can pass through the mucus barrier covering conducting airways of lung tissue — proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases.

4 Aug 2015

Prokarium receives funding to complete pre-clinical development of new Chlamydia vaccine

Prokarium Ltd, a biotechnology company developing transformational oral vaccines, today announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.

4 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

New research in mice shows that two commonly used gout medications, which target uric acid and adenosine triphosphate, may offer protection from alcohol-induced liver disease and inflammation.

3 Aug 2015

First large field trial shows VSV-ZEBOV is effective against Ebola

A vaccine against the Ebola virus, tested in West Africa for the first time in a field trial, has proved to be effective. People who had come into close contact with someone recently infected, and who are therefore at particularly high risk, were vaccinated.

3 Aug 2015

Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Tests of the experimental Ebola vaccine VSV-ZEBOV in over 7500 participants in Guinea suggest that the vaccine provides high protection against the disease as early as ten days after vaccination, in adults who have potentially been exposed to the virus by coming in close contact with a recently infected person.

31 Jul 2015

Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Results from an interim analysis of the Guinea Phase III efficacy vaccine trial show that VSV-EBOV (Merck, Sharp & Dohme) is highly effective against Ebola.

31 Jul 2015

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie.

31 Jul 2015

New synthetic gene drives could one day improve human health and the environment

Gene drives are genetic elements - found naturally in the genomes of most of the world's organisms - that increase the chance of the gene they carry being passed on to all offspring, and thus, they can quickly spread through populations. Looking to these natural systems, researchers around the world, including some Wyss Institute scientists, are developing synthetic gene drives that could one day be leveraged by humans to purposefully alter the traits of wild populations of organisms to prevent disease transmission and eradicate invasive species.

31 Jul 2015

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract, part of the body's microbiome.

31 Jul 2015

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

Oropharyngeal cancer patients who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva following cancer treatment are at an increased risk for recurrence, a study led by researchers at the Johns Hopkins Bloomberg School of Public Health has found.

31 Jul 2015

amfAR releases recommendations to help U.S. states to achieve goals of National HIV/AIDS Strategy

Major achievements have been made in the domestic HIV/AIDS response as a result of increased realignment and coordination of efforts at the federal level. However, that level of consistent coordination and alignment has yet to take place in most states. In an effort to identify what needs to be done, amfAR, The Foundation for AIDS Research, in collaboration with the National HIV/AIDS Initiative at the O'Neill Institute for National and Global Health Law at Georgetown Law, has released a set of recommendations for how states across the U.S. can improve HIV prevention and care outcomes in an effort to achieve the goals identified within the National HIV/AIDS Strategy.

31 Jul 2015

IU scientists find evidence that invisible war between microorganisms may affect human health

Health experts have warned for years that the overuse of antibiotics is creating "superbugs" able to resist drugs treating infection.

31 Jul 2015

Study shows link between liver-produced molecules, pneumonia susceptibility during sepsis

New evidence highlights the importance of the liver in immunity against bacterial pneumonia. The study is the first of its kind to directly show such a link between liver-produced molecules and pneumonia susceptibility during sepsis.

31 Jul 2015

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections.

30 Jul 2015

Hospitals penalized in HAC Reduction program may not reflect poor quality of care, shows study

Hospitals that were penalized more frequently in the Hospital-Acquired Condition (HAC) Reduction Program offered advanced services, were major teaching institutions and had better performance on other publicly reported process-of-care and outcome measures, according to a study in the July 28 issue of JAMA, a theme issue on Medicare and Medicaid at 50.

30 Jul 2015

Disease/Infection News

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Penn Medicine devises new approach to develop vaccines against lethal diseases

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Prokarium receives funding to complete pre-clinical development of new Chlamydia vaccine

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Common gout medications may offer protection from alcohol-induced liver disease, inflammation

First large field trial shows VSV-ZEBOV is effective against Ebola

Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

New synthetic gene drives could one day improve human health and the environment

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

Patients with HPV traces post-treatment more likely to have oropharyngeal cancer recurrence

amfAR releases recommendations to help U.S. states to achieve goals of National HIV/AIDS Strategy

IU scientists find evidence that invisible war between microorganisms may affect human health

Study shows link between liver-produced molecules, pneumonia susceptibility during sepsis

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Hospitals penalized in HAC Reduction program may not reflect poor quality of care, shows study

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News